Verastem Inc. Daily Stock Analysis

Daily Stock Analysis, VSTM, Verastem Inc, priceseries

Verastem Inc. Daily Stock Analysis
Stock Information
Open
1.11
Close
1.06
High
1.12
Low
1.04
Previous Close
1.10
Daily Price Gain
-0.04
YTD High
2.13
YTD High Date
Jan 4, 2022
YTD Low
1.04
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.04
YTD Gain
-49.52%
52 Week High
4.93
52 Week High Date
Jun 14, 2021
52 Week Low
1.04
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-1.16
52 Week Gain
-52.25%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 7. 2017
1.19
Mar 22. 2017
1.40
11 Trading Days
17.68%
Link
LONG
Mar 23. 2017
1.51
Apr 5. 2017
1.91
9 Trading Days
26.48%
Link
LONG
Jul 5. 2017
2.43
Jul 18. 2017
3.51
9 Trading Days
44.46%
Link
LONG
Aug 29. 2017
3.43
Sep 21. 2017
4.95
16 Trading Days
44.30%
Link
LONG
Dec 7. 2017
3.97
Dec 11. 2017
4.38
2 Trading Days
10.33%
Link
LONG
Jan 19. 2018
3.12
Feb 5. 2018
3.35
11 Trading Days
7.24%
Link
LONG
Apr 10. 2018
3.43
May 7. 2018
4.14
19 Trading Days
20.84%
Link
LONG
May 17. 2018
4.75
Jun 1. 2018
5.07
10 Trading Days
6.65%
Link
LONG
Jun 15. 2018
6.53
Jun 27. 2018
7.07
8 Trading Days
8.19%
Link
LONG
Jul 9. 2018
7.23
Jul 23. 2018
8.00
10 Trading Days
10.69%
Link
LONG
Jun 14. 2019
1.40
Jun 20. 2019
1.52
4 Trading Days
8.93%
Link
LONG
Nov 22. 2019
1.12
Dec 5. 2019
1.27
8 Trading Days
13.75%
Link
LONG
Apr 6. 2020
2.65
Apr 27. 2020
3.18
14 Trading Days
20.13%
Link
LONG
Nov 9. 2020
1.31
Dec 15. 2020
2.17
25 Trading Days
65.33%
Link
LONG
Feb 3. 2021
2.13
Feb 22. 2021
2.58
12 Trading Days
20.96%
Link
LONG
May 20. 2021
3.19
Jun 22. 2021
4.44
22 Trading Days
39.07%
Link
LONG
Sep 16. 2021
2.70
Oct 1. 2021
2.93
11 Trading Days
8.48%
Link
Company Information
Stock Symbol
VSTM
Exchange
NasdaqGM
Company URL
http://www.verastem.com
Company Phone
(781) 292-4200
CEO
Robert M. Forrester
Headquarters
Massachusetts
Business Address
117 KENDRICK STREET, SUITE 500, NEEDHAM, MA 02494
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001526119
About

Verastem, Inc. is a clinical biopharmaceutical company, which is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company is developing small molecule inhibitors of signaling pathways which includes Focal Adhesion Kinase FAK, PI3K/mTOR and Wnt that are critical to cancer stem cell survival and proliferation. Verastem was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.

Description

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways. The company's product candidate FAK inhibitor, VS-6063, is in Phase 1 study in combination with PD-1 inhibitor pembrolizumab and gemcitabine for pancreatic cancer; a Phase Ib clinical trial in combination with paclitaxel for patients with ovarian cancer; a Phase II study in patients with non-small cell lung cancer; a Phase II trial preceding surgery in mesothelioma; and a Phase 1/1b clinical trail in combination with avelumab in patients with ovarian cancer, as well as a combination trial of VS-6063 and VS-5584 in patients with relapsed mesothelioma. It is also developing FAK inhibitor, VS-4718 that is in Phase 1, single-agent, dose escalation trial in patients with advanced cancers; and a Phase 1, dose-escalation clinical trial in combination with gemcitabine and nab-paclitaxel in patients with advanced solid tumors, as well as a Phase 1, dose-escalation clinical trial of PI3K/mTORC1/2 inhibitor, VS-5584, in patients with advanced non-hematologic malignancies or lymphoma. The company has license agreement with Whitehead Institute for Biomedical Research; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is based in Needham, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading